Klotho Neurosciences, Inc. Financials

No, Klotho Neurosciences, Inc. (KLTO) reported a net income of -$10.6M in fiscal year 2025.

Klotho Neurosciences, Inc. (KLTO) reported diluted earnings per share of $-0.22 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Klotho Neurosciences, Inc. (KLTO) has a return on equity of -111.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Klotho Neurosciences, Inc. (KLTO) generated -$5.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Klotho Neurosciences, Inc. (KLTO) had $9.6M in total assets as of fiscal year 2025, including both current and long-term assets.

Klotho Neurosciences, Inc. (KLTO) invested $634K in research and development during fiscal year 2025.

Klotho Neurosciences, Inc. (KLTO) had 73M shares outstanding as of fiscal year 2025.

Klotho Neurosciences, Inc. (KLTO) had a current ratio of 95.01 as of fiscal year 2025, which is generally considered healthy.

Klotho Neurosciences, Inc. (KLTO) had a debt-to-equity ratio of 0.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Klotho Neurosciences, Inc. (KLTO) had a return on assets of -110.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Klotho Neurosciences, Inc. (KLTO) had $7.2M in cash against an annual operating cash burn of $5.9M. This gives an estimated cash runway of approximately 15 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Klotho Neurosciences, Inc. (KLTO) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Klotho Neurosciences, Inc. (KLTO) has an earnings quality ratio of 0.56x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Klotho Neurosciences, Inc. (KLTO) has an interest coverage ratio of -3.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.